• Facebook Social Icon
  • Twitter Social Icon
  • Instagram Social Icon

Mild Alzheimer's Disease - Study 2

Study Name: Mild Alzheimer’s Disease - Study 2

Clinics: Barnsley, Cannock and Manchester

Therapy Area: Alzheimer’s Disease

Gender and Age: Males and Females aged 50 - 85


MAC Clinical Research is currently conducting a clinical trial for Mild Alzheimer’s Disease. The trial objective is to evaluate the effects of administration of a new treatment on Mild Alzheimer’s Disease.

During the treatment period, participants will receive the study drug 8 times: 4 times with 4-week intervals, then 3 times with 12-week intervals, and 1 time with a 26-week interval and must attend 20 clinic visits and be available to receive 4 telephone calls.

Reimbursement: We will reimburse travel expenses or provide transport. 


Key Inclusion Criteria:

  • Age 50-85.

  • A diagnosis of mild Alzheimer’s Disease (AD) or probable Alzheimer’s.

  • Must have a project partner.

  • Received a stable AD medication for > 3 months (excluding memantine).

Key Exclusion Criteria:

  • Patients with other medical conditions that may influence cognitive impairment, including, but not limited to, vascular dementia, dementia with Lewy bodies and Parkinson’s disease.

  • History of haemorrhagic stroke, cancer and autoimmune disease.

  • History of epilepsy or unexplained seizure within the past 5 years.

  • History of major psychiatric disorder within the past 2 years, including thoughts of suicide.

Other eligibility criteria will apply. Please contact MAC for more information.

Any other information
Eligible patients will receive a comprehensive health screen and study participation will be in collaboration with the patient’s treating physician.